Comparative Pharmacology
Head-to-head clinical analysis: HYDRO RIDE versus HYDROMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO RIDE versus HYDROMOX.
HYDRO-RIDE vs HYDROMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
50-100 mg orally once daily; may increase to 200 mg/day for severe edema.
None Documented
None Documented
Terminal half-life 4-6 hours (prolonged in renal impairment).
Terminal elimination half-life: 6-9 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Renal: 70% unchanged via tubular secretion; biliary/fecal: <10%
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic